Page 119 - GHES-2-4

Global Health Economics and
Sustainability
Cost-effectiveness of oral semaglutide in Greece

Diabetologia, 61(12):2461-2498. and glycaemic control in type 2 diabetes: A meta-analysis.
Diabetes Research and Clinical Practice, 137:137-148.
https://doi.org/10.2337/dci18-0033
https://doi.org/10.1016/j.diabres.2017.12.004
Einarson, T.R., Acs, A., Ludwig, C., & Panton, U.H. (2018).
Prevalence of cardiovascular disease in type 2 diabetes: Kim, E.H., Kim, H.K., Lee, M.J., Bae, S.J., Kim, K.W., &
A systematic literature review of scientific evidence from Choe, J. (2022). Association between type 2 diabetes and
across the world in 2007-2017. Cardiovascular Diabetology, skeletal muscle quality assessed by abdominal computed
17(1):83. tomography scan. Diabetes Metabolism Research and
Reviews, 38(4):e3513.
https://doi.org/10.1186/s12933-018-0728-6
https://doi.org/10.1002/dmrr.3513
Fu, A.Z., & Sheehan, J.J. (2016). Treatment intensification for
patients with type 2 diabetes and poor glycaemic control. Makrilakis, K., Kalpourtzi, N., Ioannidis, I., Iraklianou, S.,
Diabetes, Obesity and Metabolism, 18(9):892-898. Raptis, A., Sotiropoulos, A., et al. (2021). Prevalence
of diabetes and pre-diabetes in Greece. Results of the
https://doi.org/10.1111/dom.12683
First National Survey of Morbidity and Risk Factors
Handelsman, Y., Bloomgarden, Z.T., Grunberger, G., (EMENO) study. Diabetes Research and Clinical Practice,
Umpierrez, G., Zimmerman, R.S., Bailey, T.S., et al. (2015). 172:108646.
American Association of Clinical Endocrinologists and
American College of Endocrinology-clinical practice https://doi.org/10.1016/j.diabres.2020.108646
guidelines for developing a diabetes mellitus comprehensive Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H., &
care plan 2015-executive summary. Endocrine Practice, Keen, H. (2001). Mortality and causes of death in the
21(4):413-437. WHO multinational study of vascular disease in diabetes.
Diabetologia, 44(1):14-21.
https://doi.org/10.4158/EP15672.GL
https://doi.org/10.1007/PL00002934
Hansen, B.B., Nuhoho, S., Ali, S.N., Dang-Tan, T.,
Valentine, W.J., Malkin, S.J.P., et al. (2020). Oral Pantalone, K.M., Misra-Hebert, A.D., Hobbs, T.M., Ji, X.,
semaglutide versus injectable glucagon-like peptide-1 Kong, S.X., Milinovich, A., et al. (2018). Clinical inertia in
receptor agonists: A cost of control analysis. Journal of type 2 diabetes management: Evidence from a large, real-
Medical Economics, 23(6):650-658. world data set. Diabetes Care, 41(7):e113-e114.
https://doi.org/10.1080/13696998.2020.1722678 https://doi.org/10.2337/dc18-0116
Hunt, B., Hansen, B.B., Ericsson, Å., Kallenbach, K., Ali, S.N., Pratley, R., Amod, A., Hoff, S.T., Kadowaki, T., Lingvay, I.,
Dang-Tan, T., et al. (2019). Evaluation of the cost per Nauck, M., et al. (2019). Oral semaglutide versus
patient achieving treatment targets with oral semaglutide: subcutaneous liraglutide and placebo in type 2 diabetes
A short-term cost-effectiveness analysis in the United States. (PIONEER 4): A randomised, double-blind, phase 3a trial.
Advances in Therapy, 36(12):3483-3493. The Lancet, 394(10192):39-50.
https://doi.org/10.1007/s12325-019-01125-y https://doi.org/10.1016/S0140-6736(19)31271-1
Huxley, R., Barzi, F., & Woodward, M. (2006). Excess risk of fatal Ridderstrale, M., Evans, L.M., Jensen, H.H., Bøgelund, M.,
coronary heart disease associated with diabetes in men and Jensen, M.M., Ericsson, Å., et al. (2016). Estimating the
women: Meta-analysis of 37 prospective cohort studies. impact of changes in HbA1c, body weight and insulin
BMJ, 332(7533):73-78. injection regimen on health related quality-of-life: A time
trade off study. Health and Quality of Life Outcomes,
https://doi.org/10.1136/bmj.38678.389583.7C
14(1):13.
International Diabetes Federation. (2021). IDF Diabetes
Atlas. 10 ed. Brussels, Belgium: International Diabetes https://doi.org/10.1186/s12955-016-0411-0
th
Federation. Available from: https://www.diabetesatlas.org Rodbard, H.W., Rosenstock, J., Canani, L.H., Deerochanawong, C.,
[Last accessed on 2024 Feb 20]. Gumprecht, J., Lindberg, S.Ø., et al. (2019). Oral semaglutide
versus empagliflozin in patients with type 2 diabetes
Kanavos, P., van den Aardweg, S., & Schurer, W. (2012). Diabetes
Expenditure, Burden of Disease and Management in 5 uncontrolled on metformin: The PIONEER 2 trial. Diabetes
EU Countries. LSE Health, London School of Economics. Care, 42(12):2272-2281.
Available from: https://www.lse.ac.uk/business/consulting/ https://doi.org/10.2337/dc19-0883
assets/documents/diabetes-expenditure-burden-of-disease- Rosenstock, J., Allison, D., Birkenfeld, A.L., Blicher, T.M.,
and-management-in-5-eu-countries.pdf [Last accessed on Deenadayalan, S., Jacobsen, J.B., et al. (2019). Effect of
2024 Feb 20].
additional oral semaglutide vs sitagliptin on glycated
Khunti, K., Ceriello, A., Cos, X., & De Block, C. (2018). hemoglobin in adults with type 2 diabetes uncontrolled
Achievement of guideline targets for blood pressure, lipid, with metformin alone or with sulfonylurea: The PIONEER 3

Volume 2 Issue 4 (2024) 12 https://doi.org/10.36922/ghes.3032